Integra LifeSciences (NASDAQ:IART) Releases Earnings Results, Beats Expectations By $0.02 EPS

Integra LifeSciences (NASDAQ:IART) issued its earnings results on Monday. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.02, Briefing.com reports. The business had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. Integra LifeSciences’s revenue was down .4% on a year-over-year basis. During the same period last year, the business posted $0.76 EPS.

Integra LifeSciences Stock Performance

Shares of IART traded up $1.79 during mid-day trading on Wednesday, hitting $26.70. 1,732,984 shares of the company’s stock were exchanged, compared to its average volume of 1,104,960. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17. Integra LifeSciences has a 52 week low of $16.81 and a 52 week high of $45.42. The stock’s 50-day simple moving average is $18.77 and its 200-day simple moving average is $24.38. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of 85.90, a price-to-earnings-growth ratio of 0.66 and a beta of 1.08.

Analyst Ratings Changes

Several research analysts have recently commented on IART shares. Morgan Stanley lifted their target price on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research note on Monday, July 15th. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Truist Financial dropped their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. JMP Securities reduced their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a report on Tuesday, July 30th. Finally, Citigroup increased their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Integra LifeSciences currently has a consensus rating of “Hold” and an average target price of $27.25.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.